Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc - Phase 3 SEAL Top-Line Results Conference Call Transcript

Nov 20, 2020 / 05:00PM GMT
Release Date Price: €12.95 (-2.19%)
Operator

Good day. My name is Chad, and I will be your conference operator today. At this time, I would like to welcome everyone to Karyopharm Therapeutics Phase III SEAL study results conference call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request.

I would now like to turn the conference over to Mr. Ian Karp, Karyopharm's Senior Vice President, Investor and Public Relations. Please go ahead.

Ian Karp
Karyopharm Therapeutics Inc. - SVP of Investor & Public Relations

Thanks so much, Chad, and thank you all for joining us on today's conference call to discuss the results from the Phase III SEAL study presented this morning at the Connective Tissue Oncology Society 2020 Annual Meeting. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Dr. Jatin Shah, Chief Medical Officer; and Dr. Sant Chawla, Director of the Sarcoma Oncology Center in Santa Monica, California.

On the call today, Dr. Kauffman will provide some opening remarks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot